[
  {
    "ts": "2025-07-18T21:01:22+00:00",
    "headline": "Viatris Stock Slides After Phase 3 Blepharitis Drug Trial Misses Key Target",
    "summary": "The study did not meet its main endpoint of clearing eyelid debris in blepharitis patients.",
    "url": "https://finance.yahoo.com/news/viatris-stock-slides-phase-3-210122055.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "6ef70b21-5607-3461-8682-e77fe0cdfb30",
      "content": {
        "id": "6ef70b21-5607-3461-8682-e77fe0cdfb30",
        "contentType": "STORY",
        "title": "Viatris Stock Slides After Phase 3 Blepharitis Drug Trial Misses Key Target",
        "description": "",
        "summary": "The study did not meet its main endpoint of clearing eyelid debris in blepharitis patients.",
        "pubDate": "2025-07-18T21:01:22Z",
        "displayTime": "2025-07-18T21:01:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/299a55c6fcd380acdde76abc64a0a4d8",
          "originalWidth": 550,
          "originalHeight": 412,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uIh735kyE9Sp2VFO5hRxgg--~B/aD00MTI7dz01NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/299a55c6fcd380acdde76abc64a0a4d8.cf.webp",
              "width": 550,
              "height": 412,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/otFTGMbVJjZiN61rMrhkaw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/299a55c6fcd380acdde76abc64a0a4d8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/viatris-stock-slides-phase-3-210122055.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/viatris-stock-slides-phase-3-210122055.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-18T16:25:42+00:00",
    "headline": "Why Viatris (VTRS) Stock Is Falling Today",
    "summary": "Shares of medication company Viatris (NASDAQ:VTRS) fell 3.8% in the afternoon session after its experimental therapy for blepharitis, an inflammatory condition of the eyelids, failed to meet the main goal in a late-stage study.",
    "url": "https://finance.yahoo.com/news/why-viatris-vtrs-stock-falling-162542901.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "75a6c1a8-2c23-3090-b01c-c84f0adf2ffb",
      "content": {
        "id": "75a6c1a8-2c23-3090-b01c-c84f0adf2ffb",
        "contentType": "STORY",
        "title": "Why Viatris (VTRS) Stock Is Falling Today",
        "description": "",
        "summary": "Shares of medication company Viatris (NASDAQ:VTRS) fell 3.8% in the afternoon session after its experimental therapy for blepharitis, an inflammatory condition of the eyelids, failed to meet the main goal in a late-stage study.",
        "pubDate": "2025-07-18T16:25:42Z",
        "displayTime": "2025-07-18T16:25:42Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/ad9a5e2f85d880e3e7b521395022f4d3",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "VTRS Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kZ5PSZg5aKFn_8IHve8fGQ--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/ad9a5e2f85d880e3e7b521395022f4d3.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4bPZw8EZ18ugKQPfipbnLw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/ad9a5e2f85d880e3e7b521395022f4d3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-viatris-vtrs-stock-falling-162542901.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-viatris-vtrs-stock-falling-162542901.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-18T13:11:00+00:00",
    "headline": "Major Market Benchmarks Stabilize After Clinching Record Highs, Driving Muted Premarket Action for US Equity Futures",
    "summary": "US equity futures were flat ahead of Friday's opening bell as markets took a breather after new reco",
    "url": "https://finance.yahoo.com/news/major-market-benchmarks-stabilize-clinching-131100727.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "4aeb80c3-e6d6-33de-a60b-d00866758ac5",
      "content": {
        "id": "4aeb80c3-e6d6-33de-a60b-d00866758ac5",
        "contentType": "STORY",
        "title": "Major Market Benchmarks Stabilize After Clinching Record Highs, Driving Muted Premarket Action for US Equity Futures",
        "description": "",
        "summary": "US equity futures were flat ahead of Friday's opening bell as markets took a breather after new reco",
        "pubDate": "2025-07-18T13:11:00Z",
        "displayTime": "2025-07-18T13:11:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/major-market-benchmarks-stabilize-clinching-131100727.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/major-market-benchmarks-stabilize-clinching-131100727.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CL=F"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^IXIC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-18T10:59:00+00:00",
    "headline": "Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis",
    "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis, did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing.",
    "url": "https://finance.yahoo.com/news/viatris-provides-phase-3-study-105900908.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "c85fe188-2443-3218-b0c0-05936d98ed39",
      "content": {
        "id": "c85fe188-2443-3218-b0c0-05936d98ed39",
        "contentType": "STORY",
        "title": "Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis",
        "description": "",
        "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis, did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing.",
        "pubDate": "2025-07-18T10:59:00Z",
        "displayTime": "2025-07-18T10:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/c03b6c5b724244b6bb2d566254fd974b",
          "originalWidth": 400,
          "originalHeight": 112,
          "caption": "Viatris OUS Logo (PRNewsfoto/Viatris Inc.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/q8X7v9Q2NGJ8HikeN5BEPA--~B/aD0xMTI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c03b6c5b724244b6bb2d566254fd974b.cf.webp",
              "width": 400,
              "height": 112,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g4h5fNpHKz3PzdbDqFxRYg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c03b6c5b724244b6bb2d566254fd974b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/viatris-provides-phase-3-study-105900908.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/viatris-provides-phase-3-study-105900908.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]